Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Sanofi Sa (SNY)

Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa 12/17/2025 1:38:51 AM

Sanofi's Efdoralprin Alfa Gets EMA Orphan Designation For Rare Emphysema 12/17/2025 1:23:57 AM

Sanofi : Phase 3 Tolebrutinib Trial In PPMS Did Not Meet Main Goal, No Regulatory Filing Planned 12/15/2025 1:27:48 AM

Sanofi: Regulatory Decision For Tolebrutinib To Be Delayed 12/15/2025 1:24:06 AM

Sanofi’s PERSEUS Phase 3 Trial Of Tolebrutinib In PPMS Fails Primary Endpoint; No Regulatory Filing Planned 12/15/2025 1:12:19 AM

Sanofi Expects FDA Delay On Tolebrutinib NrSPMS Review, Submits Expanded Access Protocol 12/15/2025 1:05:58 AM

Sanofi: NMPA In China Approves Qfitlia And Cablivi 12/11/2025 1:31:44 AM

Sanofi's Qfitlia And Cablivi For Rare Diseases Get China Approval 12/11/2025 1:11:19 AM

Biotech Stocks Facing FDA Decision In December 2025 11/27/2025 10:07:21 AM

Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents 11/25/2025 1:19:54 AM

Regeneron And Sanofi : European Commission Oks Dupixent As First-Line Targeted Therapy For Chronic Spontaneous Urticaria 11/25/2025 1:05:20 AM

Sanofi Gets Posiitve CHMP Opinion For Teizeild For Patients With stage 2 Type 1 Diabetes 11/14/2025 6:57:45 AM

Sanofi : CHMP Recommends Teizeild For EU Approval To Delay Stage 3 Type 1 Diabetes 11/14/2025 6:38:38 AM

Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study 11/7/2025 8:46:28 AM

Sanofi And Regeneron’s Dupixent Meets All Endpoints In Allergic Fungal Rhinosinusitis Phase 3 Trial 11/7/2025 8:07:30 AM

Novavax Completes Marketing Authorization Transfers For Nuvaxovid To Sanofi 11/4/2025 8:28:41 AM

Novavax Completes U.S. Marketing Authorization Transfer Of Nuvaxovid To Sanofi, Triggering $25 Mln Milestone 11/4/2025 8:11:30 AM

Sanofi Prices $3 Billion Notes Offering Across Five Tranches 10/28/2025 2:29:10 AM

Medidata And Sanofi Expand Collaboration To Advance Clinical Research Innovation 10/27/2025 10:29:35 PM

Medidata And Sanofi Expand Clinical Research Partnership To Accelerate Global Health Innovation 10/27/2025 10:03:46 PM

- 1
- 2
- 3
- Next »

Copyright © 2025 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap